A Double-Blind, Randomized, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of V950 Formulated on Aluminum-Containing Adjuvant With or Without ISCOMATRIX in Patients With Alzheimer Disease.
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2012
At a glance
- Drugs V 950 (Primary) ; Iscomatrix
- Indications Alzheimer's disease
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 28 Feb 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
- 28 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.